| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | -0.1 | 2.2 | 39.1 |
| Other income | 0.0 | 0.0 | 2.4 |
| Total income | -0.1 | 2.2 | 41.5 |
| Profit before exceptional items & tax | -3.5 | -2.4 | 1.8 |
| Exceptional items | 0.5 | 0.0 | 23.9 |
| Profit before tax | -4.0 | -2.4 | -22.1 |
| Net profit | -4.2 | -2.6 | -14.3 |
| Operating margin | n/m | -109.1% | -53.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: LASA. Figures extracted from the filing.
Lasa Supergenerics Ltd: key numbers
- Share price
- ₹5.89
- Market cap
- ₹29.51 Cr
- Revenue (annual)
- ₹25.14 Cr
- Net profit (annual)
- ₹-34.09 Cr
- P/E (TTM)
- -1.8×Sector 50.4×
- Promoter holding
- 53.65%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lasa Supergenerics Ltd
All →Lasa Supergenerics Annual Report
Lasa Supergenerics Ltd has submitted its 11th Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 30, 2026.
Lasa Supergenerics Annual General Meeting
Lasa Supergenerics Limited has issued a notice for its Annual General Meeting to be held on September 30, 2026, featuring seven agenda items.
Lasa Supergenerics Board Meeting Outcome
Lasa Supergenerics announced the outcome of its board meeting held on September 09, 2026. The board approved the notice for the 11th Annual General Meeting.
Lasa Supergenerics Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Narrows
Lasa Supergenerics Ltd reported revenue from operations of ₹1.2 Cr (-94.0% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹3.6 Cr